Last Updated : November 21, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Enhertu | trastuzumab deruxtecan | Metastatic HER2 positive breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Enhertu | trastuzumab deruxtecan | Metastatic HER2-positive breast cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Enhertu | trastuzumab deruxtecan | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
Enhertu | trastuzumab deruxtecan | unresectable or metastatic HER2-low breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Enspryng | satralizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
Entresto | sacubitril/valsartan | Heart failure, NYHA Class II or III | Reimburse with clinical criteria and/or conditions | Complete | ||
Entresto | Sacubitril/valsartan | Heart failure, NYHA class II or III | List with clinical criteria and/or conditions | Complete | ||
Entuzity KwikPen | human insulin | Diabetes mellitus | Reimburse with clinical criteria and/or conditions | Complete | ||
Entyvio | vedolizumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Entyvio | Vedolizumab | Ulcerative colitis | List with clinical criteria and/or conditions | Complete | ||
Entyvio | Vedolizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Epclusa | sofosbuvir / velpatasvir | Hepatitis C, chronic | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Epclusa | Sofosbuvir/ velpatasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Time-limited reimbursement recommendation | Complete | ||
Erbitux | Cetuximab | Cancelled | ||||
Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Erelzi | Etanercept | Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Erleada | Apalutamide | metastatic castration-sensitive prostate cancer (mCSPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | Do not list | Complete |